Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 26,669 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Hiatal Hernia, Paraesophageal Hernia
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: St Louis, Missouri • Portland, Oregon • Seattle, Washington

Conditions: Irritable Bowel Syndrome
Interventions: 250 mg LX1033 tablets, Placebo tablet; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 81
States / cities: Huntsville, Alabama • Tempe, Arizona • Tucson, Arizona + 75 more

Conditions: Hypertension, Smoking Cessation
Interventions: Data, Panel Management Support, Education; Other
Lead sponsor: VA New York Harbor Healthcare System; Federal
Eligibility: Not listed
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Brooklyn, New York • New York, New York

Conditions: Ulcerative Colitis, Left-sided Ulcerative Colitis, Distal Ulcerative Colitis
Interventions: Zoenasa-1:4, Mesalamine Enema; Drug
Lead sponsor: Altheus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 45
States / cities: Birmingham, Alabama • Dothan, Alabama • Lakewood, Colorado + 39 more

Conditions: Chronic Pain
Interventions: BioPlete™ Advanced Formula, Placebo; Dietary Supplement
Lead sponsor: Ethos Research & Development; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Tampa, Florida • West Palm Beach, Florida

Conditions: Alcohol Drinking, Tobacco Smoking
Interventions: Media Detective; Behavioral
Lead sponsor: Innovation Research & Training; Other
Eligibility: 7 Years to 12 Years
Enrollment: 679 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy
Interventions: PF-07264660 intravenous single ascending dose, PF-07264660 subcutaneous multiple ascending dose, Intravenous placebo, subcutaneous placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Garden Grove, California • Long Beach, California • Los Alamitos, California + 3 more

Conditions: Fibromyalgia
Interventions: milnacipran, Placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
Interventions: Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect), Lifestyle Counseling - Diet & Physical-Activity Program; Procedure · Drug · Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Heart Failure
Interventions: Finerenone (BAY94-8862), Placebo; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 40 Years and older
Enrollment: 6,016 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 107
States / cities: Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 98 more

Conditions: Contraception
Interventions: Misoprostol, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Schizophrenia
Interventions: Luvadaxistat, Matching Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Gaithersburg, Maryland

Conditions: Healthy Participants
Interventions: Simulated wildfire smoke exposure, Clean Air exposure; Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 40 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Piscataway, New Jersey

Conditions: Hypertension, Pregnancy-Induced
Interventions: furosemide, labetalol; Drug
Lead sponsor: Wright State University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Mastectomy, Gender Affirmation Surgery, Nipple Sparing Mastectomy, Prophylactic Mastectomy, Benign Breast Condition
Interventions: AmnioFix dehydrated Human Amnion/Chorion Membrane Allograft, Control Device; Device
Lead sponsor: Stanford University; Other
Eligibility: 15 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: tiotropium bromide; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 4
States / cities: Boston, Massachusetts • Rochester, Minnesota • Nashville, Tennessee + 1 more

Conditions: Analgesia
Interventions: Bupivacaine Hydrochloride, HTX-011, Luer lock applicator, Ibuprofen, Acetaminophen; Drug · Device
Lead sponsor: Heron Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 7
States / cities: Little Rock, Arkansas • Sarasota, Florida • Tulsa, Oklahoma + 4 more

Conditions: Chronic Plaque Psoriasis
Interventions: AIN457, Placebo; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 5
States / cities: Santa Monica, California • Louisville, Kentucky • High Point, North Carolina + 2 more

Conditions: Prostatic Neoplasms
Interventions: Niraparib+ Abiraterone acetate fixed dose combination (FDC), Abiraterone acetate (AA), Prednisone, Placebo FDC, Placebo AA; Combination Product · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 696 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 53
States / cities: Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more

Conditions: Kidney Transplantation
Interventions: TCD601, Tacrolimus (TAC), Corticosteroids (CS), Mycophenolate Mofetil (MMF), ATG; Biological · Drug
Lead sponsor: ITB-Med LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Atlanta, Georgia • Kansas City, Kansas • Boston, Massachusetts + 1 more

Conditions: Acute Pain, Chronic Pain
Interventions: Dexamethasone, Placebo; Drug · Other
Lead sponsor: Duke University; Other
Eligibility: 55 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pain, Postoperative
Interventions: Caffeine, Placebo oral tablet; Drug
Lead sponsor: Rothman Institute Orthopaedics; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Egg Harbor, New Jersey

Conditions: Hypercholesterolemia
Interventions: corn oil, Avocado Oil; Other
Lead sponsor: Midwest Center for Metabolic and Cardiovascular Research; Other
Eligibility: 18 Years to 74 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Postoperative Pain
Interventions: Exparel with Bubivacaine, Bupivacaine only; Drug
Lead sponsor: Jefferson Drapkin; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Brooklyn, New York

Search by objective public record fields.

Study of Paraesophageal Hernia Repair With Small Intestine Submucosa

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

Program for Research on the Outcomes of VA Education

Study of the Safety and Efficacy of Zoenasa® Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis

Evaluate the Use of the Foundation Pain Index and the Nutritional Supplement BioPlete™ in Adults With Chronic Pain

Evaluation of the Media Detective Program for Elementary School-Aged Children to Prevention Substance Use

A Preliminary Study to Evaluate PF-07264660 in Healthy Participants

A Study to Evaluate the Effects of Milnacipran on Pain Processing and Functional MRI in Patients With Fibromyalgia

Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

Intra Uterine Device Insertion in Nulliparous Women

A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia

Wildfire Related Air Pollution Exposure and Cognitive Function Pilot Study

Postpartum Management of Gestational Hypertensive Disorders Using Furosemide

The Role of Amnion Membrane Allografts in Nipple Preservation

Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients

A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. Master Protocol HTX-011-401.

Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

A Dose Escalation Study in de Novo Renal Transplantation

Dexamethasone and Pain Following Total Knee Arthroplasty

Caffeine Study for Pain Control Following Total Joint Replacement

Assessing the Effects of Corn and Avocado Oils on the Cardiometabolic Risk Factor Profile

Vaginal Cuff Infiltration With Liposomal Bupivacaine for Pain Relief: A Double Blind, Randomized Controlled Trial